Wijaya, AgustinusBo, Jiang TJun, HePing, Jiang WBin, JiangJie, Chen HWen, Yang BZhu, Xu MCheng, Qiu Q2013-10-182013-10-182012-05Wijaya Agustinus, Bo Jiang T, Jun He, Ping Jiang W, Bin Jiang, Jie Chen H, Wen Yang B, Zhu Xu M, Cheng Qiu Q. The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population. Medical Journal of Indonesia. 2012 May; 21(2): 108-112.http://imsear.searo.who.int/handle/123456789/148835Background: The aim of this study is to assess the accuracy of warfarin dosage based on VKORC1 and CYP2C9 genotype in Chinese population. Methods: Blood samples were taken from 37 patients. We compared the warfarin dosage obtained from genotype (according to www.warfarindosing.org) and treatment dosage with international normalized ratio (INR) value within 2.0-3.0. Results: The majority of Chinese people in our study are VKORC1 homozygous AA (89.2%), rarely VKORC1 heterozygous AG and we cannot find a patient with homozygous GG. For CYP2C9 genotype, most patients have the wildtype variants (CYP2C9*2 CC and CYP2C9*3 AA). The warfarin dosage for patients with VKORC1 AA and CYP2C9*3 AC is lower than for patients with other genotype variants. Conclusion: There is no significant difference between pharmacogenetic algorithm (www.warfarindosing.org) and our treatment dosage. Our conclusion is that the pharmacogenetic algorithm is accurate to predict the warfarin dose.enCYP2C9pharmacogenetic algorithmVKORC1warfarinWarfarinAsian Continental Ancestry GroupPhenotypeArticle